Prostatis Group’s CME Group CME Stock Holding History

Prostatis Group’s Portfolio CME Stock Details CME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-745	Closed	-$205K	–	167
2025 Q2	$205K	Sell	745 -378	-34%	-$103K	0.06%	154
2025 Q1	$298K	Sell	1,123 -346	-24%	-$85.3K	0.09%	121
2024 Q4	$341K	Buy	+1,469	New	+$338K	0.1%	124

Other funds holding CME

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Prostatis Group's CME Position: Q3 2025 in Review

Prostatis Group sold out of CME Group (CME) in Q3 2025, closing a stake of 745 shares — an estimated $205K sold.

Prostatis Group first reported a position in CME in Q4 2024 and held it in 3 quarters. The position peaked at $341K in Q4 2024. 1,653 funds tracked by Wall St. Rank hold CME as of Q3 2025.

Prostatis Group reported no remaining CME Group position as of Q3 2025 after selling out during the quarter.
Prostatis Group sold 745 CME Group shares in Q3 2025, an estimated $205K.
Prostatis Group first reported a position in CME Group in Q4 2024 and held it in 3 quarters.
Prostatis Group's CME Group position peaked at $341K in Q4 2024.
1,653 funds tracked by Wall St. Rank held CME Group as of Q3 2025.

Based on Prostatis Group's 13F filing for Q3 2025, filed 4 Nov 2025.